Lysine + Arginine + Ornithine + Glutamine Injection Solution (Amino Acid Gains/ (infinity) GB Shot)

Lysine + Arginine + Ornithine + Glutamine Injection Solution (Amino Acid Gains/ (infinity) GB Shot)

Available presentation(s): 10, 50 mL. Verify the exact concentration and total active quantity on the prescription and dispensing label.

Introduction: A compounded amino-acid combination containing lysine, arginine, ornithine and glutamine. It has no established approved indication or standard parenteral regimen for muscle gain or wellness.

Dosage: No validated standard dose exists. The prescription must specify the exact volume/dose, route, rate, frequency, duration, clinical objective and monitoring. Review the total amino-acid load and renal/hepatic function; do not infer dosing from the product nickname.

Mechanisms of Action: The amino acids serve as substrates for protein and nitrogen metabolism. Arginine is a nitric-oxide precursor; ornithine participates in the urea cycle; glutamine transports nitrogen; lysine is essential for protein synthesis. These biochemical roles do not establish clinical efficacy of the combination.

Contraindications & Precautions: Avoid in hypersensitivity and use caution in renal/hepatic impairment, hyperammonaemia, electrolyte disorders, hypotension, asthma and active herpesvirus disease (arginine concern is theoretical/uncertain). Assess osmolarity, pH and compatibility.

Interactions: Arginine may add to antihypertensive, nitrate or glucose-lowering effects. Potassium-sparing therapy and renal impairment may increase electrolyte risk. Interactions of the full mixture are not established.

Adverse Reactions / Side Effects: Nausea, abdominal discomfort, flushing, headache, hypotension, electrolyte/metabolic disturbance, hyperammonaemia, infusion-site pain and hypersensitivity are possible.

Pregnancy & Breastfeeding: No adequate evidence supports elective use during pregnancy or breastfeeding; avoid unless specialist nutrition support requires it.

Storage: Store under the conditions stated on the Optimus dispensing label and product-specific worksheet. Protect from light where labelled. Do not freeze unless explicitly validated. Maintain cold chain if the label requires refrigeration. Do not use after the assigned beyond-use date or if there is visible particulate matter, precipitation, colour change, loss of container integrity or evidence of improper storage. Once entered, follow the validated in-use time; do not assume a compounded vial is multi-dose.

References

• New Zealand Formulary (NZF), current online edition; product-specific approved data sheets where available; USP Pharmaceutical Compounding—Sterile Preparations; and Optimus Healthcare validated formulation, sterility/endotoxin controls and assigned beyond-use date.
• US FDA. Compounding and the FDA: Questions and Answers. Updated 16 September 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers